文献速递认知障碍与痴呆

Flortaucipir PET视觉判读的聚集tau与MCI及阿尔茨海默病临床进展风险

Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials.
PubMed 文献 · JAMA Neurol · 2021-01-01

两项前瞻性开放标签纵向研究(共364例可判读扫描的临床受损患者)评估flortaucipir PET视觉判读与约18个月临床进展的关联。结果表明该视觉判读方法可能为AD和MCI患者短期临床恶化风险提供有价值信息。

要点

  • flortaucipir PET视觉判读为晚期AD模式者18个月临床恶化风险显著高于非晚期模式。
  • 晚期AD模式组CDR-SB增加≥1分的比例为70%,非晚期组为46%(RR 1.40)。

核心结论

  • flortaucipir PET扫描经FDA批准的临床适用视觉判读方法评估,可能为AD和MCI患者18个月内临床恶化风险提供有价值信息。

研究设计与样本

  • 研究1筛选298例,入组160例基线接受flortaucipir扫描者。
  • 研究2从AMARANTH试验(因无效性分析终止)2218例中选取205例,424例随机化前后接受扫描,219例未完成18个月CDR评估被排除。
  • 两项研究共364例可判读扫描的临床受损患者,平均(SD)年龄71.8(8.7)岁,48%(174/364)为女性。

主要发现

  • 18个月随访时,晚期AD模式组70%(147/210)CDR-SB增加≥1分(预设为临床有意义恶化)。
  • 其他临床终点评估及各项研究单独数据分析均一致提示晚期AD扫描模式与更高临床恶化风险相关。

关键数值与推荐

  • flortaucipir扫描采用预设视觉判读方法评为晚期或非晚期AD模式。
  • 两项研究均以CDR-SB评分作为主要临床终点测量。
  • 临床有意义恶化预设为CDR-SB增加≥1分。

临床怎么用

  • 对临床受损的AD或MCI患者,flortaucipir PET视觉判读为晚期AD模式可提示18个月内临床恶化风险较高。
  • 该判读方法经FDA批准且临床适用,可作为短期预后评估的辅助信息。

局限性

  • 研究2来源的AMARANTH试验因无效性分析终止。
  • 研究2中219例(424例接受扫描者中)未完成18个月CDR评估而被排除。
  • 两项研究均为开放标签设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Flortaucipir positron emission tomography (PET) scans, rated with a novel, US Food and Drug Administration-approved, clinically applicable visual interpretation method, provide valuable information regarding near-term clinical progression of patients with Alzheimer disease (AD) or mild cognitive impairment (MCI). OBJECTIVE: To evaluate the association between flortaucipir PET visual interpretation and patients' near-term clinical progression. DESIGN/SETTING/PARTICIPANTS: Two prospective, open-label, longitudinal studies were conducted from December 2014 to September 2019. Study 1 screened 298 patients and enrolled 160 participants who had a flortaucipir scan at baseline visit. Study 2 selected 205 participants from the AMARANTH trial, which was terminated after futility analysis. Out of the 2218 AMARANTH participants, 424 had a flortaucipir scan around randomization, but 219 did not complete 18-month clinical dementia rating (CDR) assessments and thus were excluded. In both studies, all participants were diagnosed as clinically impaired, and they were longitudinally followed up for approximately 18 months after baseline. MAIN OUTCOMES AND MEASURES: Flortaucipir scans were rated as either advanced or nonadvanced AD pattern using a predetermined visual interpretation method. The CDR sum of box (CDR-SB) score was used as primary clinical end point measurement in both studies. RESULTS: Of the 364 study participants who had readable scans, 48% were female (n = 174 of 364), and the mean (SD) age was 71.8 (8.7) years. Two hundred forty participants were rated as having an advanced AD pattern. At 18 months follow-up, 70% of those with an advanced AD pattern (n = 147 of 210) had 1 point or more increase in CDR-SB, an event predefined as clinically meaningful deterioration. In contrast, only 46% of those with a nonadvanced AD pattern scan (n = 48 of 105) experienced the same event (risk ratio [RR], 1.40; 95% CI, 1.11-1.76; P = .005). The adjusted mean CDR-SB changes were 2.28 and 0.98 for advanced and nonadvanced AD pattern groups, respectively (P < .001). Analyses with other clinical end point assessments, as well as analyses with each individual study's data, consistently indicated a higher risk of clinical deterioration associated with an advanced AD scan pattern. CONCLUSIONS AND RELEVANCE: These results suggest that flortaucipir PET scans, when interpreted with an US Food and Drug Administration-approved, clinically applicable visual interpretation method, may provide valuable information regarding the risk of clinical deterioration over 18 months among patients with AD and MCI. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02016560 and NCT03901105.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Lu M, Pontecorvo MJ, Devous MD, et al. Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials. JAMA Neurol. 2021. PMID: 33587110. doi:10.1001/jamaneurol.2020.5505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。